Prentiss Christopher B 4
4 · Adamas Pharmaceuticals Inc · Filed Mar 23, 2021
Insider Transaction Report
Form 4
Prentiss Christopher B
Chief Accounting Officer
Transactions
- Sale
Common Stock
2021-03-22$5.48/sh−2,422$13,273→ 145,017 total
Footnotes (2)
- [F1]Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units.
- [F2]The shares were sold at prices ranging from $5.40 to $5.52. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.